FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3025120872> ?p ?o ?g. }

• W3025120872 endingPage "1255" @default.
• W3025120872 startingPage "1252" @default.
• W3025120872 abstract "Objective: To observe the clinical efficacy and the effects on serum inflammatory factors of early use of ulinastatin in patients with moderately severe or severe acute pancreatitis (MSAP/SAP). Methods: This prospective, randomized, controlled trial was conducted in the First Affiliated Hospital of Soochow University from September 2013 to May 2016. A total of 42 cases were enrolled and assigned into either observation group or conventional treatment group (n=21 each). The conventional treatment group received somatostatin, while the observation group received somatostatin combined with ulinastatin. After treatment, clinical characteristics, serum indicators, clinical complications and serum level of inflammatory factors were analyzed. Results: Intra-abdominal pressure and relief time of abdominal pain were significantly decreased in observation group [ (10.4±2.1) cmH(2)O; (2.5±1.2) d ] compared with the conventional treatment group [ (11.7±2.2) cmH(2)O; (3.33± 1.2) d ], P<0.05. White blood cells (WBC) were lower in observation group than those in conventional treatment group [ (11.2±1.8) ×10(9)/L vs (12.5±2.3) ×10(9)/L; P<0.05 ]. After treatment serum levels of interleukin-6 (IL-6), IL-8 and tumor necrosis factor-α(TNF-α) in observation group [ (30.5±3.3), (34.7± 6.5), (22.6±4.0) μg/L] were significantly lower than those in conventional treatment group [ (39.6±4.0), (40.9±3.4), (33.1±6.6) μg/L], P<0.05. There were no differences between the two groups in modified CT severity index (MCTSI), recovery time of defecation, ICU length of stay, serum amylase, C-reactive protein (CRP) and incidence rates of clinical complications. Conclusions: The early use of ulinastatin in the patients with MSAP/SAP can down-regulated the levels of TNF-α, IL-6 and IL-8, reduce the inflammatory response, decrease intra-abdominal pressure and shorten abdominal pain time. It was beneficial and worthy of wider popularization.目的： 观察早期使用乌司他丁治疗中重症/重症急性胰腺炎的疗效及对炎症因子的影响。 方法： 选择2013年9月至2016年5月期间苏州大学附属第一医院重症医学科收治的42例中重症/重症急性胰腺炎患者进行前瞻性研究。数字随机分为常规治疗组和研究组，每组21例患者。常规治疗组使用生长抑素治疗，研究组在常规治疗基础上加用乌司他丁，观察两组患者临床指标(腹内压和腹痛缓解时间)、疾病相关并发症以及血清炎症指标[白细胞、白细胞介素－6(IL－6)、IL－8、肿瘤坏死因子(TNF－α)等]变化情况。 结果： 治疗后研究组腹腔内压及腹痛缓解时间[(10.4±2.1) cmH(2)O; (2.5±1.2) d]均显著低于常规治疗组[(11.7±2.2) cmH(2)O; (3.3±1.2) d], P<0.05;白细胞计数研究组显著低于常规治疗组[(11.2±1.8)×10(9)/L与(12.5±2.3)×10(9)/L; P<0.05]；两组患者炎症指标比较，治疗后研究组患者IL－6、IL－8、TNF－α[(30.5±3.3) μg/L, (34.7±6.5) μg/L, (22.6±4.0) μg/L]均显著低于常规治疗组[(39.6±4.0)、(40.9±3.4)、(33.1±6.6) μg/L]，P<0.05，而IL－10水平两组相比差异无统计学意义。两组患者改良CT严重指数评分、恢复排便时间、重症监护病房(ICU)住院时间、血清淀粉酶、C反应蛋白以及休克、急性呼吸窘迫综合征及急性肾损害发生率比较并无显著差异。 结论： 中重症及重症急性胰腺炎患者早期使用乌司他丁进行治疗，可使患者TNF－α、IL－6、IL－8水平降低，减轻炎症反应；患者腹腔内压下降更快，腹痛缓解时间更短，改善临床症状。." @default.
• W3025120872 created "2020-05-21" @default.
• W3025120872 creator A5013483628 @default.
• W3025120872 creator A5025528013 @default.
• W3025120872 creator A5038687533 @default.
• W3025120872 creator A5052614398 @default.
• W3025120872 creator A5070445087 @default.
• W3025120872 creator A5072568779 @default.
• W3025120872 creator A5073951901 @default.
• W3025120872 creator A5082674561 @default.
• W3025120872 creator A5090887781 @default.
• W3025120872 date "2017-04-25" @default.
• W3025120872 modified "2023-09-25" @default.
• W3025120872 title "[Clinical value of the early use of ulinastatin in patients with moderately severe or severe acute pancreatitis]." @default.
• W3025120872 doi "https://doi.org/10.3760/cma.j.issn.0376-2491.2017.16.015" @default.
• W3025120872 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/28441856" @default.
• W3025120872 hasPublicationYear "2017" @default.
• W3025120872 type Work @default.
• W3025120872 sameAs 3025120872 @default.
• W3025120872 citedByCount "4" @default.
• W3025120872 countsByYear W30251208722018 @default.
• W3025120872 countsByYear W30251208722019 @default.
• W3025120872 countsByYear W30251208722020 @default.
• W3025120872 countsByYear W30251208722022 @default.
• W3025120872 crossrefType "journal-article" @default.
• W3025120872 hasAuthorship W3025120872A5013483628 @default.
• W3025120872 hasAuthorship W3025120872A5025528013 @default.
• W3025120872 hasAuthorship W3025120872A5038687533 @default.
• W3025120872 hasAuthorship W3025120872A5052614398 @default.
• W3025120872 hasAuthorship W3025120872A5070445087 @default.
• W3025120872 hasAuthorship W3025120872A5072568779 @default.
• W3025120872 hasAuthorship W3025120872A5073951901 @default.
• W3025120872 hasAuthorship W3025120872A5082674561 @default.
• W3025120872 hasAuthorship W3025120872A5090887781 @default.
• W3025120872 hasConcept C126322002 @default.
• W3025120872 hasConcept C141071460 @default.
• W3025120872 hasConcept C168563851 @default.
• W3025120872 hasConcept C2775967933 @default.
• W3025120872 hasConcept C2776297358 @default.
• W3025120872 hasConcept C2776670229 @default.
• W3025120872 hasConcept C2777785397 @default.
• W3025120872 hasConcept C2778488018 @default.
• W3025120872 hasConcept C2780678043 @default.
• W3025120872 hasConcept C2780955771 @default.
• W3025120872 hasConcept C2781246285 @default.
• W3025120872 hasConcept C42219234 @default.
• W3025120872 hasConcept C71924100 @default.
• W3025120872 hasConcept C90924648 @default.
• W3025120872 hasConceptScore W3025120872C126322002 @default.
• W3025120872 hasConceptScore W3025120872C141071460 @default.
• W3025120872 hasConceptScore W3025120872C168563851 @default.
• W3025120872 hasConceptScore W3025120872C2775967933 @default.
• W3025120872 hasConceptScore W3025120872C2776297358 @default.
• W3025120872 hasConceptScore W3025120872C2776670229 @default.
• W3025120872 hasConceptScore W3025120872C2777785397 @default.
• W3025120872 hasConceptScore W3025120872C2778488018 @default.
• W3025120872 hasConceptScore W3025120872C2780678043 @default.
• W3025120872 hasConceptScore W3025120872C2780955771 @default.
• W3025120872 hasConceptScore W3025120872C2781246285 @default.
• W3025120872 hasConceptScore W3025120872C42219234 @default.
• W3025120872 hasConceptScore W3025120872C71924100 @default.
• W3025120872 hasConceptScore W3025120872C90924648 @default.
• W3025120872 hasIssue "16" @default.
• W3025120872 hasLocation W30251208721 @default.
• W3025120872 hasOpenAccess W3025120872 @default.
• W3025120872 hasPrimaryLocation W30251208721 @default.
• W3025120872 hasRelatedWork W2352363060 @default.
• W3025120872 hasRelatedWork W2371294541 @default.
• W3025120872 hasRelatedWork W2376899852 @default.
• W3025120872 hasRelatedWork W2378573546 @default.
• W3025120872 hasRelatedWork W2384319944 @default.
• W3025120872 hasRelatedWork W2388543128 @default.
• W3025120872 hasRelatedWork W2463847124 @default.
• W3025120872 hasRelatedWork W2800029275 @default.
• W3025120872 hasRelatedWork W3025120872 @default.
• W3025120872 hasRelatedWork W3030581400 @default.
• W3025120872 hasVolume "97" @default.
• W3025120872 isParatext "false" @default.
• W3025120872 isRetracted "false" @default.
• W3025120872 magId "3025120872" @default.
• W3025120872 workType "article" @default.